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Dual Role of CREB in The Regulation 
of VSMC Proliferation: Mode of 
Activation Determines Pro- or  
Anti-Mitogenic Function
Claire Hudson1, Tomomi E. Kimura1,2, Aparna Duggirala1, Graciela B. Sala-Newby1,  
Andrew C. Newby  1 & Mark Bond1
Vascular smooth muscle cell (VSMC) proliferation has been implicated in the development of 
restenosis after angioplasty, vein graft intimal thickening and atherogenesis. We investigated the 
mechanisms underlying positive and negative regulation of VSMC proliferation by the transcription 
factor cyclic AMP response element binding protein (CREB). Incubation with the cAMP elevating 
stimuli, adenosine, prostacyclin mimetics or low levels of forksolin activated CREB without changing 
CREB phosphorylation on serine-133 but induced nuclear translocation of the CREB co-factors CRTC-2 
and CRTC-3. Overexpression of CRTC-2 or -3 significantly increased CREB activity and inhibited VSMC 
proliferation, whereas CRTC-2/3 silencing inhibited CREB activity and reversed the anti-mitogenic 
effects of adenosine A2B receptor agonists. By contrast, stimulation with serum or PDGFBB significantly 
increased CREB activity, dependent on increased CREB phosphorylation at serine-133 but not on CRTC-
2/3 activation. CREB silencing significantly inhibited basal and PDGF induced proliferation. These data 
demonstrate that cAMP activation of CREB, which is CRTC2/3 dependent and serine-133 independent, 
is anti-mitogenic. Growth factor activation of CREB, which is serine-133-dependent and CRTC2/3 
independent, is pro-mitogenic. Hence, CREB plays a dual role in the regulation of VSMC proliferation 
with the mode of activation determining its pro- or anti-mitogenic function.
Vascular smooth muscle cell (VSMC) proliferation and migration contributes towards the development of various 
vascular diseases characterised by pathological intima formation, including atherosclerosis, transplant vascu-
lopathy and pulmonary hypertension. Increased VSMC proliferation and migration also contributes towards 
restenosis after angioplasty and late vein graft failure. Interruption of this cycle can slow disease progression and 
limit pathological intima formation. This is exemplified by medications that lower low density lipoprotein (LDL) 
cholesterol or block cell proliferation, which have revolutionized preventive therapy for cardiovascular disease 
(CVD) and ameliorated the problem of angioplasty restenosis, respectively. However, these do not fully normalize 
CV risk and additional treatments are therefore needed.
The second messenger 3′-5′ cyclic adenosine monophosphate (cAMP) is synthesized in cells by adenylyl 
cyclase enzymes in response to vasoactive Gs protein-coupled receptor stimulation. In VSMC, elevated cAMP 
inhibits mitogen stimulated proliferation in vitro and after injury in vivo1–5. Inhibitory effects of cAMP on VSMC 
migration also help reduce intimal lesion formation in experimental vascular injury models6,7. Moreover, altered 
or aberrant cAMP signalling is implicated in the development of many vascular pathologies8,9, including late 
vein-graft failure10–12, angioplasty restenosis13 cardiac hypertrophy14, atherogenesis15 and pulmonary hyper-
tension. For example, the ability of VSMC to synthesise cAMP is reduced in response to hypertension16, vein 
grafting12, hypoxia and oxLDL17. cAMP levels are also reduced in blood mononuclear cells in CVD patients18. 
This suggests that deregulation of cAMP signalling is a common feature of many vascular diseases. Moreover, 
stimulation of cAMP signalling has numerous beneficial effects including reductions in neointima formation7,19, 
VSMC migration20, VSMC proliferation1,19, endothelial permeability21, inflammation, ROS generation, plasma 
triglycerides and monocyte recruitment. Therefore, treatments that elevate or mimic the action of cAMP carry 
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significant therapeutic promise because they improve endothelial function, inhibit VSMC cell proliferation and 
migration and reduce inflammation.
The anti-mitogenic effects of cAMP are mediated via activation of cAMP sensitive Protein Kinase A (PKA) 
and Exchange Protein Activated by cAMP (EPAC), which synergise to regulate levels of several cell-cycle pro-
teins2,22. However, the mechanisms downstream of PKA and EPAC are incompletely characterised. Activation 
of the cAMP sensitive transcription factor CREB may represent one important mechanism underlying 
cAMP-dependent cellular responses. Some studies have suggested anti-mitogenic properties of CREB in VSMC. 
For example, CREB levels are high in differentiated VSMC but decrease during phenotypic modulation20. Stimuli 
that enhance cAMP-signalling and inhibit VSMC proliferation and are associated with increased CREB activ-
ity22,23. Consistent with this, CREB inhibition with siRNA or dominant-negative mutants is sufficient to induce 
VSMC proliferation20,24,25, whereas overexpression of constitutively-active mutants of CREB arrests cell-cycle 
progression20,23,25. However, several other studies have reported pro-mitogenic properties of CREB in VSMC. For 
example, VSMC proliferation induced by angiotensin II26, thrombin27 or the interferon-γ inducible protein-1028 
is dependent on CREB activation. These observations suggest that CREB activation may play a role in both mito-
genic and anti-mitogenic responses in VSMC.
Phosphorylation of CREB at serine-133 is one important mechanism of CREB-mediated transcriptional acti-
vation29. PKA is implicated since this residue is part of a consensus PKA phosphorylation site (RXXS) and its 
phosphorylation can be blocked by PKA inhibition30. However, selective PKA activation fails to inhibit VSMC 
proliferation2, suggesting that PKA-mediated phosphorylation of CREB at serine-133 may not be sufficient for 
the anti-mitogenic effects of cAMP in these cells. Furthermore, several studies have also suggested that phospho-
rylation of CREB at serine-133 may not be essential for CREB-dependent gene expression, implicating alternative 
mechanisms. For example, T-cell receptor stimulation of Jurkat cells induces high levels of CREB serine-133 
phosphorylation without inducing target gene expression31. Induction of CREB activity by voltage-sensitive 
Ca2+ channels is markedly reduced in a PKA-deficient PC12 cells, despite robust CREB phosphorylation at 
serine-13332. Expression of mouse hippocampal CREB target genes in response to fear conditioning is unaffected 
in CREB-S133A transgenic mice33. Importantly, CREB can be activated independently of serine-133 phosphoryl-
ation by binding of CREB Regulated Transcription Coactivators (CRTC1, CRTC2 or CRTC3)34. However, the role 
of CRTC-regulated CREB activity in VSMC is unknown. Here, we investigated the relative importance of CREB 
serine-133 phosphorylation and nuclear translocation of CRTCs in pro- and anti-mitogenic effects on VSMCs.
Results
Forskolin and GPCR agonists induce CREB-dependent transcription independently of changes 
in CREB serine-133 phosphorylation. We initially investigated the effect of elevated cAMP levels on 
CREB-dependent gene expression and serine-133 phosphorylation using the adenylate cyclase activator for-
skolin. Stimulation of VSMC with low doses of forskolin (0.25–0.5 µM) significantly induced CREB-dependent 
reporter gene activity after 4 hours (Fig. 1A), whereas 0.1 µM forskolin did not significantly increase CREB activ-
ity. However, activation of CREB reporter activity by forskolin was not associated with an increase in CREB phos-
phorylation at serine-133 (Fig. 1B and C), despite robust PKA activation detected by increased phosphorylation 
of VASP (Fig. 1B and D). Since other studies have reported that forskolin induces serine-133 phosphorylation of 
CREB, we investigated stimulation with a supraphysiological dose of forskolin (25 µM) and confirmed that this 
did increase CREB phosphorylation at serine-133 (Supplement Fig. 1). We also verified that 0.5 µM FSK did not 
increase CREB phosphorylation over a time course from 5 to 120 minutes (Supplementary Figure 1). We next 
tested whether elevation of cAMP levels in response to physiological stimulation of adenosine A2B and pros-
tacyclin receptors also induces CREB-dependent transcription independently of changes in CREB serine-133 
phosphorylation. Stimulation of VSMC with adenosine, the adenosine-A2B receptor agonist BAY60-6583 or 
the prostacyclin receptor agonist Cicaprost significantly increased CREB-dependent reporter gene activity after 
4 hours (Fig. 1E). However, activation of CREB-dependent transcription by any of these agonists did not increase 
CREB phosphorylation at serine-133 (Fig. 1F), despite robust phosphorylation of VASP. To verify that adeno-
sine, BAY60-6583 or Cicaprost were unable to increase CREB phosphorylation at earlier time points, a detailed 
time course was conducted (Supplementary Figure 3). To confirm that elevated cAMP is able to activate CREB 
independently of serine-133 phosphorylation we tested the ability of forskolin to stimulate the activity of a GAL4 
reporter gene in cells expressing either GAL4-CREBwild-type or GAL4-CREBS133A, in which serine-133 is mutated 
to an alanine. Stimulation with 0.5 µM forskolin significantly induced GAL4 reporter activity in cells expressing 
GAL4-CREBwild-type or GAL4-CREBS133A to a similar extent (Fig. 1G). Taken together, these data imply that eleva-
tion of cAMP, either via activation of adenosine A2B or prostacyclin receptors or via adenylate cyclase activation 
with low concentrations of forskolin, induces CREB-dependent transcription independently of changes in CREB 
serine-133 phosphorylation.
PKA and EPAC act synergistically to activate CREB independently of changes in CREB serine-133 
phosphorylation. We previously demonstrated that the anti-mitogenic properties of cAMP in VSMC 
are dependent on signalling via both PKA and EPAC2. 6-BNZ-cAMP-AM (BNZ-AM) is an extremely 
membrane-permeant precursor of the specific PKA agonist 6-BNZ-cAMP. Selective activation of PKA by this 
agonist has been validated previously2,35. 8-pCPT-2′-O-Me-cAMP-AM (CPT-AM) is a membrane-permeant 
precursor of the specific EPAC agonist 8-pCPT-2′-O-Me-cAMP. Selective activation of EPAC but not PKA by 
this agonist has been validated previously2,36. In this study, stimulation with BNZ-AM or CPT-AM alone did not 
significantly increase CREB activity (Fig. 2A). However, CREB activity was significantly increased after 2 hours 
stimulation with BNZ-AM plus CPT-AM (Fig. 2A, p < 0.01), suggesting that PKA and EPAC act synergistically 
to induce CREB-dependent transcription. Importantly, selective activation of PKA, EPAC or PKA plus EPAC did 
not induce any increase in phosphorylation of CREB at serine-133 (Fig. 2B).
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Figure 1. Forskolin and GPCR agonists induce CREB-dependent transcription independently of changes in 
CREB serine-133 phosphorylation. VSMC (n = 3) were transfected with CREB-LUC, serum starved for 4 h 
before being stimulated for 4 h with indicated doses of forskolin and assayed for luciferase activity (A). VSMC 
(n = 5) were serum starved for 4 h before being treated with forskolin for 30 min; cell lysates were analysed for 
phospho-VASP, phospho-CREB and total CREB by western blotting (B) and densitometric analysis (C; n = 5 
and D; n = 4). VSMC were transfected with CREB-LUC, serum starved for 4 h before being stimulated for 4 h 
with indicated concentrations of adenosine (n = 4), BAY60-6583 (BAY, n = 6) or Cicaprost (n = 6) and assayed 
for luciferase activity (E). VSMC lysates were analysed by western blotting for phospho-VASP, pCREB and 
total CREB (F). VSMC were transfected with GAL4-NLUC together with either a GAL4, GAL4-CREBwild-type 
or GAL4-CREBS133A expression vector. Cells were serum starved for 4 hours before stimulation with 0.5 µM 
forskolin for 4 hours and subsequent nano-luciferase measurement (G, n = 5). *Indicates p < 0.05, **indicates 
p < 0.01, ***indicates p < 0.001 relative to control; one-way repeated measures ANOVA with Student Newman 
Keuls post-hoc tests.
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Forskolin and GPCR agonists induce nuclear translocation of CRTC2 and CRTC3 via PKA and EPAC. 
We investigated whether forskolin or GPCR agonist-mediated activation of CREB-dependent transcription 
is mediated by the CREB Regulated Transcription Coactivators (CRTC1, CRTC2 and CRTC3). In plasmid 
transduced, serum starved cells, GFP-tagged CRTC1, CRTC2 and CRTC3 were all predominantly cytoplas-
mic (Fig. 3A). CRTC1 remained cytoplasmic after forskolin stimulation. However, CRTC2 and CRTC3 both 
re-distributed to the nucleus within 1 hour of forskolin stimulation (Fig. 3A and B). We therefore focused our 
attention on CRTC2 and CRTC3. Activation of adenosine A2B receptors with adenosine or BAY60-6583 and 
prostacyclin receptors with Cicaprost also resulted in a significant nuclear translocation of CRTC2 and 3 (Fig. 3C 
and D). We next used cellular fractionation to confirm that these stimuli induce a similar nuclear transloca-
tion of endogenous CRTC2 and CRTC3 proteins. Separation of cytosolic and nuclear proteins was effective, 
as demonstrated by the exclusive localisation of GAPDH and Lamin A/C in these respective fractions (Fig. 3E 
and F). Stimulation with BAY60-6583 or Cicaprost resulted in a rapid (within 20 minutes) nuclear translocation 
of CRTC2 and CRTC3 (Fig. 3E–H). High dose forskolin (10 µM) was included as a positive control and to aid 
quantification. We next stimulated cells with the PKA and EPAC selective agonists, BNZ-AM or CPT-AM, to test 
if these cAMP effectors regulate CREB activity by cooperating to induce CRTC nuclear translocation. Selective 
activation of EPAC, with CPT-AM did not significantly induce nuclear localisation of CRTC2 or CRTC3. In con-
trast, selective activation of PKA with BNZ-AM resulted in a significant but sub-maximal induction of nuclear 
localisation of CRTC2 and CRTC3. Importantly, this was significantly enhanced by co-activation of EPAC, indi-
cating a synergistic action of these proteins on CRTC2 and CRTC3 activation (Fig. 4A–D).
CRTC2 and CRTC3 activate CREB-independently of serine-133 phosphorylation and inhibit 
VSMC proliferation. Elevated cAMP has well documented anti-mitogenic effects in VSMC1,2,19,22. We there-
fore investigated the role of cAMP/CRTC-dependent CREB activation on VSMC proliferation and migration. We 
utilised three approaches to activate and inhibit CRTCs: adenovirus mediated expression of constitutively-active 
CRTC2 (Ad:CRTC2S171A) or CRTC3 (Ad:CRTC3S161A); pharmacological inhibition of Salt Inducible Kinase (SIK), 
which phosphorylates CRTC and represses activation; and siRNA-mediated silencing of CRTC2 and CRTC3. 
Infection of VSMC with Ad:CRTC2S171A or Ad:CRTC3S161A resulted in equal expression of FLAG-tagged CRTC2 
and CRTC3 protein (Fig. 5A) and a significant increase in CREB activity (Fig. 5B). Expression of active CRTC2 
and CRTC3 also stimulated the expression of the classical CREB target genes Nr4A, Crem, Sik and Has (Fig. 5C) 
without altering cell viability (Fig. 5D). Active CRTC2 and CRTC3 also stimulated the activity of a GAL4-reporter 
in cells expressing GAL4-CREBwild-type and this was not significantly different in cells expressing GAL4-CREBS133A 
(Fig. 5E). Furthermore, dual silencing of both CRTC2 and CRTC3 prevented induction of CREB activity in 
response to forskolin, BAY60-6583 or Cicaprost (Fig. 5F). These data indicate that activation of CRTC2 and 
CRTC3 is responsible for CREB activation in response to cAMP-elevating stimuli in VSMC and that this occurs 
independently of CREB serine-133 phosphorylation.
In a real-time scratch wound migration assays, neither CRTC2 nor CRTC3 affected the rate of VSMC 
migration over 24 hours (Supplement Fig. 4). However, expression of either active-CRTC2 or active-CRTC3 
Figure 2. PKA and EPAC act synergistically to activate CREB independently of changes in CREB serine-133 
phosphorylation. VSMC were transfected with CREB-LUC, serum starved for 4 h before being stimulated for 
2 h with 2 µM 8-CPT-2′-O-Me-cAMP-AM (CPT) to activate EPAC, 4 µM 6-Bnz-cAMP-AM (BNZ) to activate 
PKA, or both, then assayed for luciferase activity (n = 3; A). VSMC were serum starved for 4 hours before being 
treated with the CPT and/or BNZ for 30 min. Cell lysates were used for western blotting and densitometric 
analysis with pCREB and total CREB antibodies (n = 3; B).
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Figure 3. Forskolin and GPCR agonists induce nuclear translocation of CRTC2 and CRTC3. VSMC were 
transfected with GFP-CTRC1, 2 or 3 by electroporation and after 24 h were serum starved for 24 h. Cells were 
stimulated for 1 h with 0.5 µM forskolin (A and B, n = 3), 100 µM adenosine (n = 4; C,D), 5 µg/ml BAY60-
6583 (BAY, n = 4; C,D), or 1 µM Cicaprost (n = 4; C,D). Cells were analysed for cellular localisation of CRTC 
proteins by fluorescence microscopy and image analysis. Data were expressed as % of cells with predominantly 
nuclear CRTC protein. VSMC (n = 6) serum starved for 4 h were treated for 20 or 60 min with 5 µg/ml BAY, 
1 µM Cicaprost (CICA) or 10 µM forskolin (FSK). Cells were subjected to cytosolic and nuclear fractionation 
and proteins were subjected to SDS-PAGE and western blotting for CRTC2, CRTC3, Lamin A/C and GAPDH 
(E and F). CRTC2 and CRTC3 levels were quantified by densitometry and data were expressed relative to FSK 
(nucleus, G) or CONT (cytosol, H). *Indicates p < 0.05, ***indicates p < 0.001 relative to control; one-way 
repeated measures ANOVA with Student Newman Keuls post-hoc tests.
www.nature.com/scientificreports/
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significantly decreased proliferation in an asynchronous population of VSMC as determined by BrdU incorpo-
ration (40.5 ± 4.0% BrdU positive compared to 21.8 ± 4.5% and 30.6 ± 4.2% for CRTC2 and CRTC3 respectively, 
p < 0.05, Fig. 6A). Moreover, after serum starvation, active CRTC2 significantly decreased serum-induced prolif-
eration (from 40.1 ± 3.8 to 10.0 ± 3.5%) or platelet derived growth factor (PDGFBB)-induced proliferation (from 
28.5 ± 1.5 to 12.9 ± 1.4%, both p < 0.001, Fig. 6B and C). Active CRTC3 significantly decreased serum-induced 
proliferation (40.1 ± 3.8 to 24.5 ± 3.7%, p < 0.05) and resulted in a small decrease in PDGFBB-induced prolif-
eration that was not statistically significant (Fig. 6B and C). We next employed pharmacological inhibition of 
SIK, using the highly selective SIK inhibitor HG-9-91-0137 to activate endogenous CRTC proteins. SIK-mediated 
phosphorylation of CRTC proteins is reported to induce their cytoplasmic sequestration by 14-3-3ε and thus 
their inactivation38. Consistent with this, SIK inhibition with HG-9-91-01 reduced cytoplasmic levels of endog-
enous CRTC2 and CRTC3 and induced their accumulation in the nuclear fraction (Fig. 6D). HG-9-91-01 treat-
ment also significantly increased CREB activity (Fig. 6E) and significantly inhibited VSMC proliferation (Fig. 6F).
To further investigate the role of CRTC2 and CRTC3 in mediating the anti-mitogenic effects of 
cAMP-elevating signals, we tested the ability of the adenosine A2B receptor agonist BAY60-6583 to inhibit prolif-
eration of VSMC in which both CRTC2 and CRTC3 had been silenced. In siNegative transfected cells, treatment 
with BAY60-6583 resulted in a significant inhibition of BrdU incorporation (from 29.36 ± 1.70 to 14.03 ± 3.00%; 
p < 0.01 n = 4; Fig. 6G). In siCRTC2/3 transfected cells, basal proliferation rates were not significantly different 
from siControl transfected cells (29.36 ± 1.70 vs 29.11 ± 2.76% respectively). However, BAY60-6583 stimulation 
did not significantly inhibit proliferation in siCRTC2/3 transfected cells and proliferation rates after BAY60-6583 
Figure 4. PKA and EPAC act synergistically to induce nuclear translocation of CRTC2 and CRTC3. VSMC 
were transfected with GFP-CRTC 2 (n = 4; A and B) or GFP-CRTC3 (C and D) by electroporation and serum 
starved for 24 h. Cells were stimulated for 1 h with 2 µM 8-CPT-2′-O-Me-cAMP-AM to activate EPAC, 4 µM 
6-Bnz-cAMP-AM to activate PKA or both together. Cells were analysed for cellular localisation of CRTC 
proteins by fluorescence microscopy and image analysis. Data were expressed as % of transfected cells with 
nuclear CRTC2 (B) or CRTC3 (n = 3; D) protein. *Indicates p < 0.05, ***indicates p < 0.001 relative to control; 
one-way repeated measures ANOVA with Student Newman Keuls post-hoc tests.
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stimulation were significantly lower in siControl transfected cells compared to CRTC2/3 silenced cells (Fig. 6G). 
Taken together, these data demonstrate that CRTC2 and CRTC3 contribute to the anti-mitogenic effects of cAMP 
in VSMC. Finally, we tested if these anti-mitogenic effects of CRTC2 and CRTC3 are mediated via activation of 
CREB, given that CRTC proteins have also been reported to interact with several other transcription factors39,40. 
To this end, we tested the ability of active CRTC2 to inhibit proliferation in VSMC where CREB was silenced. 
Adenovirus-mediated expression of constitutively active-CRTC2 significantly inhibited proliferation in siControl 
transfected cells (Fig. 6H). Importantly, constitutively active-CRTC2 did not affect proliferation in CREB-silenced 
cells, indicating the CREB is essential for the anti-mitogenic effects of CRTC2 (Fig. 6H). Interestingly, CREB 
silencing also significantly reduced the basal proliferation rate of Ad:Control infected cell.
Figure 5. CRTC2 or CRTC3 mediate cAMP induced CREB activity. VSMC were infected with control 
adenovirus (Ad:control) or adenovirus expressing active-CRTC2 (Ad:CRTC2) or active-CRTC3 (Ad:CRTC3) 
and equal expression verified by western blotting with an anti-FLAG antibody (A, n = 4). Cells were transfected 
with CREB-LUC and 24 h later infected with CRTC or control adenovirus, luciferase activity was measured in 
cell lysates after 24 h (B, n = 4). mRNA levels of NR4A, CREM, SIK and HAS were assessed in Ad:CRTC2 or 3 
infected cells by RT-qPCR (C, n = 4), and cell viability determined using trypan blue after 48 h viral expression 
(D, n = 4). VSMC were transfected with GAL4-NLUC together with either a GAL4, GAL4-CREBwild-type or 
GAL4-CREBS133A expression vector. Cells were infected with adenoviruses expressing constitutively active 
CRTC2 or CRTC3 and GAL4-NLUC activity quantified 24 hours later (E). VSMC were co-transfected with 
CREB-LUC reporter and scrambled siRNA (siNEG) or siRNA against CRTC2 and CRTC3 (siCRTC2/3). After 
48 hours, cells were serum starved for 4 h before being treated with forskolin (FSK, 0.5 µM; n = 3), BAY60-6583 
(BAY, 1 µg/ml; n = 3) or Cicaprost (CICA, 1 µM; n = 3) for 4 h. Cells were lysed for luciferase measurement (F). 
Data were analysed with one-way ANOVA with Student Newman Keuls post-tests; **indicates p < 0.01 relative 
to control, ##indicates p < 0.01 relative to siNEG.
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Figure 6. Expression of active CRTC2/3 inhibits VSMC proliferation but not migration, and CRTC2/3 contribute 
to cAMP-induced inhibition of proliferation. Asynchronously proliferating cells in 5% FCS were infected 
with control adenovirus (Ad:control) or adenovirus expressing active-CRTC2 (Ad:CRTC2) or active-CRTC3 
(Ad:CRTC3) for 24 h and incubated for a further 6 h with 10 µM BrdU to label proliferating cells (A, n = 4). VSMC 
expressing active CRTC2 or CRTC3 were serum starved for 24 h and proliferation was stimulated with 5% FCS (B, 
n = 5) or 25 ng/ml PDGFBB (C, n = 7) for 24 h, with BdrU present during the final 6 h. Serum-starved VSMC were 
stimulated with 2 µM HG-9-91-01 for 45 min and nuclear translocation of endogenous CRTC2 and CRTC3 was 
analysed by cell fractionation and western blotting (D). VSMC were transfected with CREB-LUC and serum starved 
for 18 hours ± 2 µM HG-9-91-01. CREB-LUC was quantified in cell lysates (E). Asynchronously proliferating 
cells were stimulated with 2 µM HG-9-91-01 for 24 hours with BrdU present for the final 6 hours (F). VSMC were 
transfected with scrambled siRNA (siNEG) or siRNA against CRTC2 and CRTC3 (siCRTC2/3) and grown in 5% 
FCS for 24 h. Cells were treated with 1 µg/ml BAY60-6583 (BAY) for 24 h with BrdU present for the final 6 h to 
label cells (G, n = 4). VSMC were transfected with siNEG or siRNA against CREB. Cells were then infected with 
Ad:control or Ad:CRTC2. Proliferation was quantified 24 hours later by labelling with BrdU for 6 hours (n = 4; H).
www.nature.com/scientificreports/
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Mitogen induced CREB-activity is CRTC-independent, associated with increased serine-133 
phosphorylation and required for VSMC proliferation. We next investigated if mitogenic stimuli 
also induced CREB-dependent transcription and if this was mediated by CRTC activation or increased CREB 
serine-133 phosphorylation. Stimulation with 5% serum significantly increased CREB activity after 2 hours 
and this persisted for at least 6 hours (Fig. 7A). Stimulation with PDGFBB also significantly increased CREB 
activity after 2, 4 and 6 hours, although to a lesser extent than that induced by 5% serum. Stimulation with 5% 
serum resulted in a rapid and significant increase in CREB phosphorylation at serine-133 within 15 minutes 
(p < 0.01 at 15 min) and this persisted for 60 minutes (Fig. 7B). PDGFBB stimulation also significantly induced 
CREB phosphorylation at serine-133 but this was slightly delayed compared to serum stimulation, being signif-
icant after 30 minutes and persisting for 2 hours (Fig. 7B). To determine which kinases are involved in mediat-
ing mitogen-induced serine-133 CREB phosphorylation we treated cells with a panel of pharmacological kinase 
inhibitors of mitogen-regulated kinases. Inhibition of AKT (using MK2206), PI3-Kinase (using LY294002) or p38 
MAPK (using SB 203580) did not significantly affect CREB phosphorylation at serine-133 (Fig. 7C). Inhibition of 
JNK (using SP600125) resulted in a small but significant increase in CREB phosphorylation. However, inhibition 
of MEK (using U0126) or conventional PKCs (using bisindolylmaleimide I) strongly and significantly inhibited 
CREB phosphorylation in response to PDGFBB stimulation (Fig. 7C). To determine if mitogen induced activation 
of CREB is dependent on serine-133 phosphorylation we tested the ability of serum to stimulate the activity of 
a GAL4 reporter gene in cells expressing either GAL4-CREBwild-type or GAL4-CREBS133A, in which serine-133 is 
mutated to an alanine. Serum stimulation resulted in a significant induction of GAL4 reporter activity in cells 
expressing GAL4-CREBwild-type but not in cells expressing GAL4-CREBS133A (Fig. 7D). We also tested if mitogen 
induced activation of CREB is associated with activation of CRTC2 or CRTC3. Serum or PDGFBB stimulation did 
not result in any detectable increase in nuclear levels of endogenous CRTC2 or CRTC3 (Fig. 7E and Supplement 
Fig. 5). Together, these data imply that induction of CREB activity by mitogens, in contrast to cAMP elevating 
stimuli, is dependent on MEK and PKC dependent phosphorylation of CREB at serine-133 but independent of 
CRTC2 and CRTC3 activation.
CREB activity contributes to mitogen-stimulated proliferation of VSMC. To test whether CREB 
activity is required for mitogen-stimulated VSMC proliferation, we silenced CREB in VSMC using siRNA. 
Transfection with CREB targeting siRNA reduced CREB protein levels below the limit of detection by Western 
blotting without affecting levels of GAPDH protein (Fig. 8A). This reduction in CREB protein expression was 
associated with a significant decrease in serum- and PDGFBB-mediated CREB reporter activity (Fig. 8B and C, 
both p < 0.001). CREB silencing also significantly reduced proliferation of an asynchronous population of VSMC 
as determined by BrdU incorporation (Fig. 8D, 22± to 13±% in siNEG versus siCREB, p < 0.01). Moreover, 
CREB siRNA inhibited both serum- (Fig. 8E) and PDGF-induced (Fig. 8F) increases in proliferation (40± to 
33±% and 32± to 23±% respectively, both p < 0.05). These data demonstrate that mitogen-stimulated activation 
of CREB, which is dependent on serine-133 phosphorylation, is required for efficient VSMC proliferation.
Discussion
In this study, we investigated the role played by CREB phosphorylation at serine-133 and the CREB co-factors, 
CRTC2 and CRTC3, in mediating the pro- or anti-mitogenic effects of elevated cAMP in vascular smooth muscle 
cells. We demonstrated that cAMP elevating signals can activate CREB-dependent transcription independently 
of CREB phosphorylation at serine-133 by inducing nuclear translocation of CRTC2 and CRTC3. Furthermore, 
this CRTC-mediated activation of CREB is anti-mitogenic. Importantly, we also demonstrate a pro-mitogenic 
function of CREB in response to serum or PDGFBB stimulation. This is regulated independently of CRTC activa-
tion and instead dependent on increased phosphorylation of CREB at serine-133. Our data suggests that CREB 
plays a dual role in controlling VSMC proliferation and that the mode of CREB activation dictates its pro- or 
anti-mitogenic function in these cells (Fig. 9).
The physiological effects of increased CREB activity in VSMC have been debated for a long time. Many studies 
have demonstrated that levels of CREB are down regulated in response to a range of cardiovascular risk factors 
and mitogenic signals15,20,41, suggesting that CREB plays an important role in maintaining normal VSMC physi-
ology and repressing proliferation. For example, levels of CREB are reduced in response to aging, hypertension, 
hyperlipidaemia15 and diabetes41. CREB levels negatively correlate with the proliferative capacity of VSMC, being 
high in differentiated VSMC but reduced in phenotypically modulated cells20. Many studies have demonstrated 
that cAMP-elevating stimuli, which potently activate CREB-dependent-transcription, inhibit VSMC prolifera-
tion1,2,19,22,42. Consistent with this, forced expression of a constitutively-active CREB fused to the viral activation 
domain VP16, inhibits VSMC proliferation20. Taken together, these observations suggest that elevated levels of 
CREB protein and activity repress VSMC proliferation. In contrast, there are many reports that CREB can also be 
activated by mitogenic stimuli in VSMC. For example, CREB is activated in response to angiotensin II or throm-
bin stimulation and VSMC proliferation in response to these mitogens is CREB-dependent26,27. This suggests that 
CREB plays a dual role in regulating VSMC proliferation and raises the question of how a CREB can control both 
pro- and anti-mitogenic responses.
The canonical pathway of CREB activation involves phosphorylation of CREB on serine-133 in the 
kinase-inducible domain43. This facilitates interaction with CREB binding protein CBP and has been reported to 
be required for activation of CREB-dependent gene expression29. Elevation of cAMP with forskolin in various cell 
types induces CREB phosphorylation at serine-133 and increases CREB-dependent transcription30,44–46. However, 
these studies use high concentrations of forskolin (typically 10–25 µM), which induce supra-physiological levels 
of cAMP in VSMC4. Consistent with these findings, we were also able to detect increased serine-133 phospho-
rylation in VSMC stimulated with 25 µM forskolin (Supplement Fig. 1). However, we demonstrated that low 
concentrations of forskolin (0.25–0.5 µM) or physiological GPCR agonists induce CREB-dependent transcription 
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Figure 7. Mitogen induce activation of CREB is serine-133 phosphorylation dependent but CRTC independent. 
VSMC were transfected with CREB-LUC and serum starved for 24 hours. Cells were stimulated with 5% serum 
or 25 ng/ml PDGFBB for the indicated times and luciferase activity quantified (n = 3; A). VSMC serum starved for 
4 h were stimulated for 5, 15, 30, 60 or 120 min with 5% FCS or 25 ng/ml PDGFBB (B) or pre-treated with UO126 
(UO, 10 µM), MK-2206 (MK, 10 µM), LY294002 (LY, 10 µM), Bisindolylmaleimide I (BIS1, 5 µM), SB 203580 
(SB, 10 µM) or SP600125 (SP, 10 µM) and then stimulated with PDGF for 30 min (C). Phosphorylated CREB was 
detected in cell lysates by western blotting with a pCREB (S133) antibody, membranes were reprobed with a total 
CREB antibody. Phospho-CREB bands were quantified by densitometry and expressed relative to the maximum 
value in each individual experiment. VSMC were transfected with GAL4-NLUC together with either a GAL4, 
GAL4-CREBwild-type or GAL4-CREBS133A expression vector and serum starved for 24 hours before stimulation with 
5% serum for 4 hours (n = 5; D). VSMC (n = 6) serum starved for 4 h were treated for 20 or 60 min with 5% FCS 
or 25 ng/ml PDGF. Cells were subjected to fractionation and nuclear extracts analysed by Western blotting and 
densitometry for CRTC2 and CRTC3 (E). *Indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001 relative 
to non-stimulated; one-way repeated measures ANOVA with Student Newman Keuls post-hoc tests.
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in VSMC without increasing CREB phosphorylation at serine-133, suggesting that a non-canonical pathway con-
trols cAMP-induced CREB activity in these cells. We demonstrated that these physiological cAMP signals induce 
CREB activation by stimulating the nuclear translocation of the CREB co-factors, CRTC2 and CRTC3, whereas 
CRTC1 did not translocate to the nucleus in response to cAMP elevation. Stimulation with low concentrations 
of forskolin, Cicaprost, adenosine or the adenosine A2B-receptor agonist BAY60-6583, all stimulated nuclear 
translocation of CRTC2 and CRTC3, without increasing CREB serine-133 phosphorylation. Furthermore, exper-
iments with selective activators of PKA and EPAC demonstrated that these cAMP-sensitive pathways act syner-
gistically to induce CRTC2/3 activation and CREB activity, mirroring their synergistic action inhibiting VSMC 
proliferation2. To our knowledge this is the first time that EPAC has been linked to the regulation of CRTCs or 
CREB activation. The precise mechanism underlying this regulation remains unclear. However, it is unlikely 
to involve EPAC-dependent modulation of PKA activity because we previously demonstrated that EPAC acti-
vation does not enhance PKA-mediated phosphorylation of VASP or kemptide in these cells2. Expression of 
constitutively active CRTC2 or CRTC3 activated CREB whereas siRNA-mediated CRTC silencing completely 
blocked forskolin or GPCR-agonist induced CREB activity, demonstrating that CRTC activation was essential for 
CREB-dependent transcription in response to cAMP elevating stimuli in VSMC.
To the best of our knowledge, nothing has previously been reported regarding the function of CRTCs 
in VSMC. In other cell types, activation of CRTCs have been linked to various cellular functions including 
regulation of gluconeogenesis, lipid metabolism, myogenic gene expression47, and fasting-dependent long 
term memory48. Here, using constitutively active mutants of CRTC2 and CRTC3, siRNA-mediated silenc-
ing and pharmacological inhibition of SIK, we demonstrate for the first time that activation of CRTC2 and 
CRTC3 inhibits VSMC proliferation. Interestingly, VSMC migration was not affected by CRTC activation. 
Furthermore, siRNA-mediated silencing of CRTC2 and CRTC3 reverses the growth inhibitory effects of 
cAMP-elevating stimuli, linking CRTC activation to the anti-mitogenic effects of cAMP in VSMC. This is in 
Figure 8. CREB activity contributes to mitogen-stimulated proliferation of VSMC. VMSC were transfected 
with control siRNA (siNEG) or siRNA targeting CREB (siCREB) and knockdown verified by western blotting 
after 48 h using anti-CREB and GAPDH antibodies (A). Cells were co-transfected with CREB-LUC and siNEG 
or siCREB. 24 h after transfection cells were serum starved for 3 h, followed by stimulation with 5% FCS (B, 
n = 6) or 25 ng/ml PDGFBB (C, n = 6) for 4 h and luciferase activity measured. Asynchronously proliferating 
VSMC were transfected with siNEG or siCREB. 24 hours post-transfection, cells were incubated with 10 µM 
BrdU (D, n = 5); or serum starved for 30 h then stimulated with 5% FCS (E, n=) or 25 ng/ml PDGFBB (F, n=) 
for 24 h, with BrdU present during the final 6 h to label cells. Cells transfected with siNEG or siCREB for 24 h 
were subsequently infected with Ad:control or Ad: CRTC2 for 24 h and incubated with BrdU for 6 h to label 
proliferating cells (G). *Indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001; one-way repeated 
measures ANOVA with Student Newman Keuls post-hoc tests.
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contrast to β-cells, where CRTC2 promotes proliferation, suggesting cell-type specific differences in CRTC 
function49. Although CRTC proteins were initially identified as CREB co-factors34, recent reports demon-
strate that CRTCs can interact with other transcription factors, including MEIS1A39 and STAT340. However, 
our data showing that CREB-silencing abolishes the anti-mitogenic effects of CRTC2 demonstrates that their 
anti-mitogenic properties are mediated via their CREB co-factor function in VSMC. Taken together, our data 
demonstrates for the first time that the anti-mitogenic effects of cAMP-elevating stimuli in VSMC occur inde-
pendently of CREB serine-133 phosphorylation and are instead mediated, at least in part, via CRTC2 and 
CRTC3-dependent activation of CREB activity.
Importantly, we also provide evidence that CREB plays a role in promoting VSMC proliferation in response 
to mitogen stimulation. CREB-activity was increased in response to serum or PDGFBB stimulation. However, this 
was associated with and dependent on increased phosphorylation at serine-133, in contrast to cAMP induced 
CREB activation. Moreover, mitogen stimulation did not induce nuclear translocation of CRTC2 or CRTC3. This 
suggests that mitogens and cAMP employ different mechanisms to activate CREB in VSMC. Importantly, CREB 
silencing inhibited both basal proliferation and serum or PDGFBB stimulated proliferation. This suggests that 
CREB plays a dual role in regulating VSMC proliferation and that the mode of CREB activation determines the 
pro- or anti-mitogenic function. Activation of CREB by CRTC2 or CRTC3 in response to cAMP elevating stimuli 
occurs independently of CREB serine-133 phosphorylation and promotes growth arrest. In contrast, activation of 
CREB by in response to mitogenic growth factors is dependent on increased CREB serine-133 phosphorylation, 
is CRTC independent and is required for efficient proliferation.
The transcription factor CREB is emerging as an important player in the development of vascular disease and 
intima formation. Our new data highlights the dual role that CREB plays controlling VSMC proliferation and 
identifies the CRTC-CREB pathway that selectively controls the anti-mitogenic functions of CREB. Future work 
should focus on determining if this pathway is amenable to pharmacological manipulation, possibly via inhibi-
tion of SIK, to exploit the potential vascular protective effects of intervening in this pathway.
Methods
Materials. All chemicals were obtained from Sigma unless otherwise stated. Antibodies to CREB (#9104), 
phospho S133 CREB (#9196), VASP (#3132), CRTC3 (#2720) and Lamin A/C (#4777) were from Cell Signaling 
Technologies. Antibodies to GAPDH (#MAB374) and CRTC2 (#ST1099) were from Merck-Millipore. 
Figure 9. Schematic representation illustrating the mechanisms underlying the pro- and anti-mitogenic 
functions of CREB in VSMC. Stimuli that elevate cAMP activate PKA and EPAC synergise to induce 
nuclear translocation of CRTC2 and CRTC3 and activate of CREB. This occurs independently of CREB 
phosphorylation at serine-133 and contributes towards the anti-mitogenic properties of cAMP in VSMC. 
Growth factors also induce CREB activation. This is dependent on increased phosphorylation of CREB at 
serine-133 but independent of CRTC2 or CRTC3 activation. This mechanism is regulated by MEK and PKC and 
is pro-mitogenic.
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Anti-BrdU antibody (B2531) was from Sigma Aldrich. Silencer® Select siRNA targeting CRCT2 and CRTC3 
(#4390791 and #4390771 respectively) and negative control (#4390843) were purchased from Thermo Fisher. 
ON-TARGETplus SMARTpool CREB siRNA (#L-092995-02-0005) and ON-TARGETplus Non-targeting Control 
Pool (#D-001810-10-05) were purchased from Dharmacon. UO126, LY294002, SB 203580 were from Merck-
Calbiochem. Bisindolylmaleimide I (BIS1, GF 109203×) was purchased from Tocris Bioscience. MK-2206 was 
from Selleckchem. HG-9-91-01 was a gift from Dr Kris Clark (University of Dundee)37. Forskolin was purchased 
from Sigma Aldrich. BAY60-658350 and Cicaprost were purchased from Caymen Chemical. PDGF-BB was pur-
chased from R&D systems. 6-BNZ-cAMP-AM35, a cell permeable selective PKA agonist, and 8-pCPT-2′-O-Me-
cAMP-AM, a cell permeable selective EPAC super-agonist36, were purchased from Biolog.
Smooth muscle cell culture. All experiments were performed using different batches of cells that were 
prepared from different animals. Male Sprague Dawley rats were killed by cervical dislocation in accordance with 
the Directive 2010/63/EU of the European Parliament, under schedule 1 of the United Kingdom Home Office 
Animal Scientific Procedures Act 1986 and performed in accordance with guidelines, regulations and approval 
of the University of Bristol. Approval was granted by the University of Bristol ethical review board. Cultures of 
rat aortic VSMCs (RaVSMCs) were prepared as previously described51 Stimulations were performed in serum 
free DMEM unless otherwise stated. Cells were serum starved for 18 hours or 4 hours, as indicated in figure 
legends. Proliferation was measured by culture in the presence of 10 µM bromodeoxyuridine (BrdU) for 6 hours. 
Following fixation in 70% ethanol, incorporated BrdU was detected by immune-histochemical staining as previ-
ously described2. Typically, all cells (at least 200) in five to ten fields of view were manually counted using ImageJ 
software. For nuclear and cytosolic fractionation, cells were lysed with ice-cold hypotonic lysis buffer (10 mM 
HEPES pH 7.8, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 × protease (Complete) and phosphatase (PhosTOP) 
inhibitor mix (Roche Diagnostics Ltd)). After incubation for 20 min on ice with regular vortexing, nuclei were 
pelleted at 2000 g at 4 °C and the supernatant was collected as the cytosolic fraction. After washing the pellet 
in lysis buffer containing 0.1% NP40, nuclear proteins were extracted in SDS lysis buffer (1% SDS, 10 mM Tris 
pH6.8, 10% glycerol).
Real-time scratch wound migration assays. Real-time analysis of migration was performed using a IncuCyte® 
ZOOM live cell imaging system (Essen BioScience) according to the manufacturer’s instructions. Briefly, 
RaVSMCs were seeded at 2 × 104 cells/well for into ImageLock-96 well plates (Essen Bioscience). Wells were 
scratched using a WoundMaker® tool and phase contrast images of cell migration into the wounded area acquired 
hourly for 24 hours. Relative wound confluence was calculated using the Cell Migration Image analysis module 
of the IncuCyte® ZOOM software.
Plasmids and Adenoviral Vectors. CREB reporter plasmid (CREB-LUC; α-168) was a gift from Prof 
Stan McKnight52. FLAG-CRTC1, FLAG-CRTC2 and FLAG-CRTC3 plasmids were a gift from Dr Nina Balthasar 
(University of Bristol). GFP-CRTC-1, -2 and -3 plasmids were constructed by sub-cloning CRTC-1, -2 or -3 
cDNAs into pEGFP-N1 expression vector (Clontech). For adenoviruses expressing constitutively active CRTC2 
(S171A) or CRTC3 (S162A), cDNAs were cloned into pDC515 (Microbix) and adenoviruses generated as previ-
ously described2. GAL4-Nano-luciferase plasmid (GLA4-NLUC) was created by sub-cloning the 5xGAL4 binding 
elements from plasmid pG5E1b-LUC (a gift from Ugo Moens) into the Nhe1 and Xho1 sites of pNL3.3[secN-
luc/minP] (Promega). pcDNAI-GAL4-CREBwild-type and pcDNAI-GAL4-CREBS133A expression vectors were 
obtained from Addgene (#46769 and #46771 respectively)30.
Quantitative RT-PCR and Western Blotting. Quantification of mRNA and protein levels was performed 
by RT-qPCR and western blotting respectively, as described previously2. Total RNA, extracted using Ambion 
Pure-Link kits (Thermo Fisher) and was reverse transcribed using QuantiTect RT kit (Qiagen) and random prim-
ers. Quantitative PCR was performed using Roche SYBR Green using a Qiagen Roto-Gene Q PCR machine 
(20′@95 °C; 20′@62 °C; 20′@72 °C). Primers sequences are described in Supplement Table 1. Data were normal-
ised to non-stimulated controls. Western blots were performed using a Mini-Protean II system. Proteins were 
transferred to PVDF membrane using wet transfer and detected using ECL (Luminata Forte, Millipore) and a 
digital ChemiDoc imaging system (Bio-Rad).
Transient transfection and reporter gene assays. CREB activity was determined by quantifying the 
luciferase reporter activity in cells transfected with CREB-LUC (α-168), which contains 168 bp of the endoge-
nous alpha polypeptide glycoprotein hormones gene (CGA) promoter containing two identical repeats of the 
8-bp core CRE52,53. Plasmid transfection was performed by electroporation using an Amaxa Nucleofector-1.5. 
1 × 106 VSMCs were transfected with 5 μg of DNA or 100 pmoles of siRNA using the standard Nucleofector 
program A033. Cells were stimulated with the indicated agents 24 hours post transfection followed by lysis 
in Promega cell culture lysis buffer or for secreted nano-luciferase reporters cell culture media collected and 
assays using NanoGlow assay system (Promega). Luciferase and Renilla activity were quantified using the dual 
reporter assay kit (Promega) according to the manufactures instructions using Glomax Discover luminometer 
(Promega).
Statistical Analysis. Statistical analysis was performed using two-way ANOVA, one-way ANOVA with 
Student-Newman-Keuls post-test or where appropriate a paired student’s t-test, as indicated. *Indicates p < 0.05, 
**indicates p < 0.01, ***indicates p < 0.001.
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